Advaxis Executive Reshuffle Following Asset Sale
Company Announcements

Advaxis Executive Reshuffle Following Asset Sale

Advaxis (ADXS) has provided an update.

Ayala Pharmaceuticals, Inc. finalized a major asset sale on March 25, 2024, leading to the departure of Chief Medical Officer Andres Guttierez. Following this transaction, Roy Golan, the Chief Financial Officer, also agreed to leave the company, with his departure set for June 25, 2024. This strategic move marks a significant reshuffling of Ayala’s executive team amidst its latest corporate developments.

For an in-depth examination of ADXS stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyImmunome price target raised to $33 from $27 at Wedbush
TipRanks Auto-Generated NewsdeskAdvaxis Enhances Operations Through Strategic Asset Sale
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App